ECCMID 25th (2015)

Title Content type
An open-label phase 3 study of Isavuconazole (VITAL): focus on patients with mixed fungal infections (click for details)
Drug interaction profiles of Isavuconazole, voriconazole and posaconazole with immunosuppressants metabolized by CYP4503A4 (CYP3A4) – (click for details)
A comparison of the safety profiles of Isavuconazole vs voriconazole in the phase 3 SECURE study in patients with invasive mould infections – (click for details)
Successful treatment of contaminated epidural steroid associated fungal meningitis with Isavuconazole (click for details)
Safety and outcomes in obese patients with invasive fungal disease treated with Isavuconazole in the phase 3 randomised double-blind SECURE trial – (click for details)
Safety and outcomes in invasive aspergillosis patients with renal vs. no renal impairment treated with Isavuconazole: experience from the SECURE (randomized) and VITAL trials (click for details)
Outcome of invasive aspergillosis after allogeneic haematopoietic stemcell transplantation in patientswith invasive aspergillosis before transplantation (click for details)
Clone of Bis(metil)gliotoxin detection in patients at risk of invasive aspergillosis correlates with higher mortality and use of antifungals (click for details)
Chronic pulmonary aspergillosis (CPA) is likely to be a common complication of pulmonary tuberculosis: initial results of a cross-sectional survey (click for details)
Fibrosis as a complication of chronic pulmonary aspergillosis (click for details)


Subscribe to ECCMID 25th (2015)